首页> 美国卫生研究院文献>Biomolecules Therapeutics >Microfluidic System Based High Throughput Drug Screening System for Curcumin/TRAIL Combinational Chemotherapy in Human Prostate Cancer PC3 Cells
【2h】

Microfluidic System Based High Throughput Drug Screening System for Curcumin/TRAIL Combinational Chemotherapy in Human Prostate Cancer PC3 Cells

机译:基于微流体系统的高通量药物筛选系统用于姜黄素/ TRAIL联合化学疗法治疗人前列腺癌PC3细胞

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We have developed a fully automated high throughput drug screening (HTDS) system based on the microfluidic cell culture array to perform combinational chemotherapy. This system has 64 individually addressable cell culture chambers where the sequential combinatorial concentrations of two different drugs can be generated by two microfluidic diffusive mixers. Each diffusive mixer has two integrated micropumps connected to the media and the drug reservoirs respectively for generating the desired combination without the need for any extra equipment to perfuse the solution such as syringe pumps. The cell array is periodically exposed to the drug combination with the programmed LabVIEW system during a couple of days without extra handling after seeding the cells into the microfluidic device and also, this device does not require the continuous generation of solutions compared to the previous systems. Therefore, the total amount of drug being consumed per experiment is less than a few hundred micro liters in each reservoir. The utility of this system is demonstrated through investigating the viability of the prostate cancer PC3 cell line with the combinational treatments of curcumin and tumor necrosis factor-alpha related apoptosis inducing ligand (TRAIL). Our results suggest that the system can be used for screening and optimizing drug combination with a small amount of reagent for combinatorial chemotherapy against cancer cells.
机译:我们已经开发了基于微流控细胞培养阵列的全自动高通量药物筛选(HTDS)系统,以进行联合化疗。该系统具有64个可单独寻址的细胞培养室,可以通过两个微流体扩散混合器产生两种不同药物的连续组合浓度。每个扩散混合器都有两个集成的微型泵,分别连接到介质和药物储器,以产生所需的组合,而无需任何其他设备来灌注溶液,例如注射泵。在将细胞接种到微流控设备中之后,细胞阵列会在几天内定期与编程的LabVIEW系统接触药物组合,而无需额外的处理,而且与以前的系统相比,该设备不需要连续产生溶液。因此,每个储罐中每个实验消耗的药物总量少于几百微升。通过研究前列腺癌PC3细胞系与姜黄素和肿瘤坏死因子-α相关的凋亡诱导配体(TRAIL)联合治疗的可行性,证明了该系统的实用性。我们的结果表明,该系统可用于筛选和优化与少量试剂组合用于针对癌细胞的化学疗法的药物组合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号